Personalized medicine for depression: can we match patients with treatments?
- PMID: 20843873
- PMCID: PMC3723328
- DOI: 10.1176/appi.ajp.2010.09111680
Personalized medicine for depression: can we match patients with treatments?
Abstract
Objective: Response to specific depression treatments varies widely among individuals. Understanding and predicting that variation could have great benefits for people living with depression.
Method: The authors describe a conceptual model for identifying and evaluating evidence relevant to personalizing treatment for depression. They review evidence related to three specific treatment decisions: choice between antidepressant medication and psychotherapy, selection of a specific antidepressant medication, and selection of a specific psychotherapy. They then discuss potential explanations for negative findings as well as implications for research and clinical practice.
Results: Many previous studies have examined general predictors of outcome, but few have examined true moderators (predictors of differential response to alternative treatments). The limited evidence indicates that some specific clinical characteristics may inform the choice between antidepressant medication and psychotherapy and the choice of specific antidepressant medication. Research to date does not identify any biologic or genetic predictors of sufficient clinical utility to inform the choice between medication and psychotherapy, the selection of specific medication, or the selection of a specific psychotherapy.
Conclusions: While individuals vary widely in response to specific depression treatments, the variability remains largely unpredictable. Future research should focus on identifying true moderator effects and should consider how response to treatments varies across episodes. At this time, our inability to match patients with treatments implies that systematic follow-up assessment and adjustment of treatment are more important than initial treatment selection.
Conflict of interest statement
Dr. Simon has no financial interest to disclose.
In the past 10 years, Dr. Perlis has served as an advisory board member, or received consulting or speaking fees, from the following companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., Glaxo SmithKline, Proteus Biomedical, and Pfizer. He holds equity and receives royalties from Concordant Rater Systems.
Figures
Similar articles
-
Targeting treatments for depression: what can our patients tell us?Epidemiol Psychiatr Sci. 2017 Feb;26(1):37-39. doi: 10.1017/S2045796016000160. Epub 2016 Apr 5. Epidemiol Psychiatr Sci. 2017. PMID: 27044431 Free PMC article. No abstract available.
-
Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents.Cochrane Database Syst Rev. 2012 Nov 14;11:CD008324. doi: 10.1002/14651858.CD008324.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 Nov 30;(11):CD008324. doi: 10.1002/14651858.CD008324.pub3. PMID: 23152255 Updated. Review.
-
Are personalised treatments of adult depression finally within reach?Epidemiol Psychiatr Sci. 2017 Feb;26(1):40-42. doi: 10.1017/S204579601600007X. Epub 2016 Mar 11. Epidemiol Psychiatr Sci. 2017. PMID: 26965477 Free PMC article. No abstract available.
-
Continuation and maintenance treatments for depression in older people.Cochrane Database Syst Rev. 2012 Nov 14;11:CD006727. doi: 10.1002/14651858.CD006727.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152240 Review.
-
Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review.Depress Anxiety. 2012 Oct;29(10):855-64. doi: 10.1002/da.21985. Epub 2012 Jul 19. Depress Anxiety. 2012. PMID: 22815247 Review.
Cited by
-
Validity and reliability of the Depression Information Needs Scale among the Iranian general population.Front Psychiatry. 2024 Sep 3;15:1388447. doi: 10.3389/fpsyt.2024.1388447. eCollection 2024. Front Psychiatry. 2024. PMID: 39290305 Free PMC article.
-
Probiotics and Fecal Microbiota Transplantation in Major Depression: Doxa or Episteme?Adv Exp Med Biol. 2024;1456:67-83. doi: 10.1007/978-981-97-4402-2_4. Adv Exp Med Biol. 2024. PMID: 39261424 Review.
-
Executive functioning as a predictor of response to interpersonal psychotherapy in adolescents with depression: A pilot study.J Affect Disord Rep. 2022 Dec;10:100376. doi: 10.1016/j.jadr.2022.100376. Epub 2022 Jul 3. J Affect Disord Rep. 2022. PMID: 39184534 Free PMC article. No abstract available.
-
A systematic review of predictors and moderators of treatment outcomes in internet- and mobile-based interventions for depression.Internet Interv. 2024 Jul 21;37:100760. doi: 10.1016/j.invent.2024.100760. eCollection 2024 Sep. Internet Interv. 2024. PMID: 39139716 Free PMC article. Review.
-
Neuroimaging for precision medicine in psychiatry.Neuropsychopharmacology. 2024 Nov;50(1):246-257. doi: 10.1038/s41386-024-01917-z. Epub 2024 Jul 22. Neuropsychopharmacology. 2024. PMID: 39039140 Review.
References
-
- Depression Guideline Panel. Clinical Practice Guideline Number 5: Depression in Primary Care. Rockville, MD: U.S. Dept of Health and Human Services, Agency for Health Policy and Research; 1993. AHCPR Publication No 93-0550.
-
- Parikh S, Lam R CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001. 2001;46:13S–76S. - PubMed
-
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision) Am J Psychiatry 2000. 2000;157:s1–s45. - PubMed
-
- Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008 Nov 18;149(10):734–50. - PubMed
-
- Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746–58. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
